Articles

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Department of Hematology, Vall d’Hebron University Hospital, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra
Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Sevilla
Department of Hematology, Hospital Clínico Universitario de Salamanca, IBSAL, Salamanca
Department of Hematology, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia
Department of Hematology, Hospital Clínic, Barcelona
Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria
Department of Hematology, Hospital Universitario 12 de Octubre, Madrid
Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, Barcelona
Department of Hematology, Hospital Universitari Germans Trias i Pujol, Instituto Catalán de Oncología, Josep Carreras Research Institute, Badalona
Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Department of Hematology, Vall d’Hebron University Hospital, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra
Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Sevilla
Department of Hematology, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria
Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia
Department of Hematology, Hospital Universitario 12 de Octubre, Madrid
Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid
Department of Hematology, Vall d’Hebron University Hospital, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra
Department of Hematology, Hospital Universitari Germans Trias i Pujol, Instituto Catalán de Oncología, Josep Carreras Research Institute, Badalona
Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, Barcelona
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona
Department of Hematology, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia
Department of Hematology, Hospital Clínic, Barcelona
Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Universidad Complutense de Madrid
Department of Hematology, Hospital Clínico Universitario de Salamanca, IBSAL, Salamanca
Department of Hematology, Vall d’Hebron University Hospital, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra
Haematologica Early view Jun 30, 2022 https://doi.org/10.3324/haematol.2022.280805